NIKKEI 225
37,666.43 -793.65 (-2.06%) HANG SENG
17,261.26 +59.99 (+0.35%) CRUDE OIL
82.94 +0.13 (+0.16%) GOLD FUTURES
2,328.10 -10.30 (-0.44%) DOW
38,460.92 -42.77 (-0.11%) Bitcoin GBP
51,356.04 -2,237.35 (-4.17%)
Marinus Pharmaceuticals, Inc. (MRNS)
After hours:
| Previous close | 1.4400 |
| Open | 1.4400 |
| Bid | 1.4300 x 2200 |
| Ask | 1.4600 x 5100 |
| Day's range | 1.3900 - 1.4600 |
| 52-week range | 1.1100 - 11.2600 |
| Volume | |
| Avg. volume | 1,741,572 |
| Market cap | 79.101M |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
RADNOR, Pa., April 15, 2024--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that an independent Data Monitoring Committee (DMC) has recommended continuing the pivotal Phase 3 RAISE trial evaluating intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE) following an interim analysis.
- Business Wire
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
RADNOR, Pa., April 05, 2024--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the grant of inducement awards to two new employees. The Compensation Committee of the Board of Directors of Marinus approved the grant of non-qualified stock options to purchase an aggregate of 47,400 shares of its common stock (the "Common Stock") as inducements material to the employees entering
- Business Wire
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
RADNOR, Pa., March 27, 2024--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to developing and commercializing innovative therapeutics to treat seizure disorders, today affirmed its commitment to defending its patent portfolio amidst an Inter Partes Review (IPR) challenge of U.S. Patent 11,110,100 from Ovid Therapeutics, Inc. filed on March 26, 2024. This challenge relates to a Marinus patent for the use of ganaxolone in treating status epilepticus (SE) and refra
